| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[23] Carbamazepine, oral: Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017 Dec 15;12:CD011412. https://www.ncbi.nlm.nih.gov/pubmed/29243813
Carbamazepine, oral: South African Medicines Formulary, 12th Edition. Division of Clinical Pharmacology. University of Cape Town, 2016.
Carbamazepine, oral (titration therapy): Nag D, Garg RK, Agarwal A. A comparative evaluation of pharmacokinetics of conventional and slow-release carbamazepine formulation in newly treated patients of epilepsy: a random evaluation. J Assoc Physicians India. 1998 Feb;46(2):185-8. https://www.ncbi.nlm.nih.gov/pubmed/11273108
Carbamazepine, oral (maintenance therapy): Powell G, Saunders M, Rigby A, Marson AG. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Cochrane Database Syst Rev. 2016 Dec 8;12:CD007124. https://www.ncbi.nlm.nih.gov/pubmed/27933615